New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
12:24 EDTRNAProsensa accelerated or conditional approvals likely, says Roth Capital
Roth Capital said its is "increasingly optimistic" that regulators won't focus on the outcome of Prosensa's disappointing phase 3 study for drisapersen and are likely to consider the totality of the data given the rare disease setting. The firm believes accelerated or conditional approvals for the drug are likely and it reiterates its Buy and $17 price target on the stock.
News For RNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
07:04 EDTRNAProsensa reports Q3 EPS (EUR 0.29) vs. (EUR 0.12) last year
November 14, 2014
16:19 EDTRNAGIMV reports 1.43% passive stake in Prosensa
November 10, 2014
15:53 EDTRNACredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 11 at 10:30 am; not all company presentations may be webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use